¼¼°èÀÇ ½ÃÀå ÀÚÀ²½Å°æ Á¦¾î ½ÃÀå
Cardiac Autonomic Control
»óǰÄÚµå : 1758834
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,106,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,320,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÃÀå ÀÚÀ²½Å°æ Á¦¾î ¼¼°è ½ÃÀåÀº 2030³â±îÁö 234¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 164¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÃÀå ÀÚÀ²½Å°æ Á¦¾î ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 234¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½É¹Ú º¯µ¿ ¸ð´ÏÅÍ´Â CAGR 4.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 110¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç÷¾Ð ¸ð´ÏÅÍ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 43¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR6.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÃÀå ÀÚÀ²½Å°æ Á¦¾î ½ÃÀåÀº 2024³â 43¾ï ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 38¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.0%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 5.5%¿Í 5.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½ÃÀå ÀÚÀ²½Å°æ Á¦¾î ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå¿äÀÎ Á¤¸®

½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀÌ ½ÉÇ÷°ü Áø´Ü, ¸¸¼ºÁúȯ °ü¸®, ½Å°æÁ¶Àý¿ä¹ý¿¡¼­ Àü·«Àû Á߿伺ÀÌ ³ô¾ÆÁö´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÀÓ»óÀǵéÀÌ ÀÚÀ²½Å°æ°è(ANS)¿Í ½ÉÀå ±â´ÉÀÇ »óÈ£ ÀÛ¿ëÀ» ´õ Àß ÀÌÇØÇÏ°í °ü¸®Çϱâ À§ÇØ ³ë·ÂÇϸ鼭 ½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀº Á¡Á¡ ´õ °í±Þ ½ÉÇ÷°ü Ä¡·áÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ »ý¸®Àû ¿µ¿ªÀº ½É¹Ú¼ö, ¸®µë, Ç÷°ü ±äÀåµµÀÇ ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æÀÇ Á¶Àý°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ½ÉºÎÀü, ºÎÁ¤¸Æ, °íÇ÷¾Ð, üÀ§¼º ºó¸Æ ÁõÈıº(POTS), ½ÉÀå µ¹¿¬»ç µîÀÇ º´Å»ý¸®¸¦ À¯¹ßÇÏ´Â ÀÚÀ²½Å°æ ±â´É Àå¾Ö¸¦ ¹ß°ßÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¸¸¼º »ýȰ½À°üº´ ¹× ½ºÆ®·¹½º °ü·Ã ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÉÀå ÀÚÀ²½Å°æ Ȱµ¿À» Æò°¡Çϰí Á¶ÀýÇÏ´Â Áø´Ü µµ±¸ ¹× Ä¡·á ÁßÀç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½É¹Úº¯µ¿(HRV), ¾Ð·Â ¹Ý»ç ¹Î°¨µµ, ÀÚÀ²½Å°æ ±äÀåµµ µîÀÇ ½ÉÀå ÀÚÀ²½Å°æ ¹ÙÀÌ¿À¸¶Ä¿´Â ½ÉÇ÷°ü Áúȯ, ´ë»ç¼º Áúȯ, ½Å°æÅðÇ༺ Áúȯ ȯÀÚÀÇ Á¶±â À§Çèµµ ºÐ·ù, Ä¡·á ÃÖÀûÈ­, ¿¹ÈÄ ¿¹Ãø¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­·Î ÀÎÇØ ½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀº ¿¹¹æ, °³º°È­, ½Å°æ½ÉÀåÇÐ ÅëÇÕ Ä¡·á¸¦ À§ÇÑ ±¤¹üÀ§ÇÑ Àü·«¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù.

¸ð´ÏÅ͸µ ±â¼ú, AI ºÐ¼®, ´º·Î¸ðµâ·¹ÀÌ¼Ç ¼Ö·ç¼ÇÀº ½ÉÀå ÀÚÀ²½Å°æ Á¦¾î ¿ëµµ¸¦ ¾î¶»°Ô ¹ßÀü½Ã۰í Àִ°¡?

±â¼úÀº ½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀ» ÃøÁ¤ÇÏ°í °ü¸®ÇÏ´Â ¹æ¹ýÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ½ÉÀüµµ ¸ð´ÏÅÍ, ¿¬¼Ó HRV ÃßÀû ½Ã½ºÅÛ, À̽ÄÇü ·çÇÁ ·¹ÄÚ´õ, ½º¸¶Æ® ÆÐÄ¡´Â ¿Ü·¡ ȯ°æ¿¡¼­ ÀÚÀ²½Å°æ ¸¶Ä¿¸¦ ºñħ½ÀÀûÀ¸·Î ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ ÀåÄ¡µéÀº Àå±âÀûÀÎ ¸®µë ÃßÀû, ½ºÆ®·¹½º ¹ÝÀÀ ºÐ¼®, ÀÚÀ²½Å°æ ±â´É Æò°¡¸¦ Áö¿øÇϸç, º´¿ø¿¡¼­ º¹ÀâÇÑ °Ë»ç¸¦ ÇÊ¿ä·Î ÇÏÁö ¾Ê½À´Ï´Ù.

AI¿Í ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ÀÚÀ²½Å°æ µ¥ÀÌÅÍ ºÐ¼®À» °­È­ÇÏ¿© °³ÀÎÈ­µÈ ±âÁؼ±, ÀÌ»ó ¡ÈÄ °¨Áö, ½ÉÀå »ç°Ç¿¡ ´ëÇÑ ¿¹Ãø ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ´Â °íÀ§Ç豺 ½ÉÀ庴 ȯÀÚ, ¿îµ¿¼±¼ö, ÀÚÀ²½Å°æÀå¾Ö ȯÀÚÀÇ ¿ø°Ý ¸ð´ÏÅ͸µ¿¡ ƯÈ÷ À¯¿ëÇÏ°Ô È°¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. Ä¡·á Ãø¸é¿¡¼­´Â ¹ÌÁֽŰæÀÚ±Ø(VNS), ô¼öÀÚ±Ø, »ýüÀüÀÚº¯Á¶ µîÀÌ ½ÉºÎÀü, ½É¹æ¼¼µ¿, ÀúÇ×¼º °íÇ÷¾ÐÀÇ ÀÚÀ²½Å°æ ±ÕÇüÀ» ȸº¹Çϱâ À§ÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

¾à¸®ÇÐÀû ¿¬±¸µµ ÀÚÀ²½Å°æ ±äÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾à¹°¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ÅëÇÕ µðÁöÅÐ Ç÷§ÆûÀº HRV ºÐ¼®°ú ½ºÆ®·¹½º ¹× ½ÉÀå ÀçȰ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ÇൿÀû °³ÀÔÀ» °áÇÕÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ ½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀº ÀÓ»ó ÇöÀå°ú À£´Ï½º ȯ°æ Àü¹Ý¿¡ °ÉÃÄ ½Ç¿ëÀûÀ̰í È®Àå °¡´ÉÇÑ °ÍÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù.

½ÉÀå ÀÚÀ²½Å°æ Á¦¾î ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ÀÓ»ó ¿ëµµ, Áö¿ª ½ÃÀå, °øµ¿ ¿¬±¸´Â ¹«¾ùÀΰ¡?

½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀº ÀÓ»ó½ÉÀ庴ÇÐ, ½ºÆ÷Ã÷ÀÇÇÐ, ¼ö¸éÀÇÇÐ, ³»ºÐºñÇÐ, ½Å°æÇп¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÉºÎÀü °ü¸®, ºÎÁ¤¸Æ Áø´Ü, ´ç´¢º´¼º ÀÚÀ²½Å°æÀå¾Ö ½ºÅ©¸®´×, ½É±Ù°æ»ö ÈÄ À§Çèµµ °èÃþÈ­ µîÀÌ ÁÖ¿ä ÀÌ¿ë »ç·ÊÀÔ´Ï´Ù. ½ºÆ÷Ã÷ °úÇп¡¼­´Â HRV ¸ð´ÏÅ͸µÀÌ ÈÆ·Ã ºÎÇϸ¦ ÃÖÀûÈ­ÇÏ°í °úÈÆ·ÃÀ» ¹æÁöÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çൿ °Ç°­ÇÐ ¹× ¹ÙÀÌ¿ÀÇǵå¹é ¿ëµµ¿¡¼­´Â ÀÚÀ²½Å°æ¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Ȱ¿ëÇÏ¿© ºÒ¾ÈÀå¾Ö, PTSD, ¹ø¾Æ¿ô ÁõÈıº¿¡ ´ëÇÑ °³ÀÔÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì¿Í À¯·´Àº Áø´Ü ¹× ½Å°æÁ¶Àý ±â¼ú ¸ðµÎ¿¡¼­ ¿¬±¸, ÀÓ»ó äÅÃ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀο¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ƯÈ÷ ÀϺ», Çѱ¹, Áß±¹¿¡¼­ ¸ð¹ÙÀÏ Çコ¿ÍÀÇ ÅëÇÕ°ú ¿þ¾î·¯ºí ±â¼ú äÅÃÀ» ÅëÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Çаè, ÀÇ·á ±â¼ú ±â¾÷, ½ÉÀ庴 ¼¾ÅÍ °£ÀÇ °øµ¿ ¿¬±¸ °³¹ßÀº Á¦Ç° °³¹ß ¹× ÀÚÀ²½Å°æ°è ¸¶Ä¿ÀÇ ÀÓ»ó Æò°¡ÁöÇ¥·Î¼­ÀÇ °ËÁõÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ Çコ °ü·Ã ½ºÅ¸Æ®¾÷, À£´Ï½º ±â±â Á¦Á¶¾÷ü, ½ÉÀå ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç Á¦°ø¾÷üµéÀº ÀÚÀ²½Å°æ ±â´É¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÏ´Â HRV ±â¹Ý Ç÷§ÆûÀ» Áß½ÉÀ¸·Î Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ÁöºÒÀÚ¿Í ÀÇ·á ½Ã½ºÅÛÀº ¸¸¼ºÁúȯ °ü¸®¿Í ÀçÀÔ¿ø °¨¼Ò¿¡ ÀÖ¾î ÀÚÀ²½Å°æ°è µ¥ÀÌÅÍÀÇ °¡Ä¡¸¦ ÀνÄÇϱ⠽ÃÀÛÇßÀ¸¸ç, ÁÖ·ù Áø·á ¸ðµ¨¿¡ ÀÚÀ²½Å°æ°è µ¥ÀÌÅ͸¦ ÅëÇÕÇÏ´Â °ÍÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

½ÉÀå ÀÚÀ²½Å°æ Á¦¾î ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½ÉÀå ÀÚÀ²½Å°æ Á¶Àý ½ÃÀåÀº ÀÚÀ²½Å°æ ±â´É Àå¾ÖÀÇ ¿ªÇÒÀÌ ½ÉÇ÷°ü °á°ú, ¸¸¼ºÁúȯ ºÎ´ã, Çൿ°Ç°­°ú ´õ¿í ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÊ¿¡ µû¶ó È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¸ð´ÏÅ͸µ ¹× ½Å°æ Á¶Àý ±â¼úÀÇ Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÓ»óÀû ÀÇ»ç°áÁ¤ ¹× ÀÚ°¡ °ü¸® ¸ðµ¨·ÎÀÇ ÅëÇÕÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ½ÉÇ÷°ü Áúȯ À¯º´·ü Áõ°¡, Á¶±â Áø´Ü ¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä, ¿þ¾î·¯ºí °Ç°­ ±â¼úÀÇ ºÎ»ó, ºñħ½ÀÀû ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç °³¹ß, ÀÚÀ²½Å°æ Á¶ÀýÀÇ Ä¡·á °¡´É¼º µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ´ÙÇÐÁ¦Àû ¿¬±¸¿Í µðÁöÅÐ ±â¼ú Çõ½ÅÀ¸·Î °³ÀÎÈ­µÈ ÀÚÀ²½Å°æ ÇÁ·ÎÆÄÀϸµÀÇ »õ·Î¿î ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ½Ã½ºÅÛÀÌ Á¤¹ÐÀÇ·á¿Í ½Ç½Ã°£ »ý¸®Àû ÅëÂû·ÂÀ¸·Î ÀüȯÇÏ´Â °¡¿îµ¥, ½ÉÀå ÀÚÀ²½Å°æ Á¶ÀýÀÌ ½ÉÇ÷°ü ¹× ½Å°æÇൿÇÐÀû °Ç°­ °³ÀÔÀ» ¿¹Ãø, ¿¹¹æ ¹× °³ÀÎÈ­Çϱâ À§ÇÑ ±âÃÊÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ ÇÁ·¹ÀÓ¿öÅ©·Î ºÎ»óÇÒ ¼ö ÀÖÀ»±î?

ºÎ¹®

Á¦Ç° À¯Çü(½É¹Ú º¯µ¿ ¸ð´ÏÅÍ, Ç÷¾Ð ¸ð´ÏÅÍ, ECG ¸ð´ÏÅÍ, ±âŸ Á¦Ç° À¯Çü), ¿ëµµ(Áø´Ü, Ä¡·á, ¿¬±¸), ÃÖÁ¾ ¿ëµµ(º´¿ø ¹× Ŭ¸®´Ð, °¡Á¤¿ë, ¿¬±¸±â°ü, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 44°³»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À º¯¾Ð±â Ŭ¸³Æ®, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è µµ¸ÞÀÎ ÀͽºÆÛÆ®·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cardiac Autonomic Control Market to Reach US$23.4 Billion by 2030

The global market for Cardiac Autonomic Control estimated at US$16.4 Billion in the year 2024, is expected to reach US$23.4 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Heart Rate Variability Monitors, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Blood Pressure Monitors segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 6.0% CAGR

The Cardiac Autonomic Control market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Cardiac Autonomic Control Market - Key Trends & Drivers Summarized

Why Is Cardiac Autonomic Control Gaining Strategic Importance Across Cardiovascular Diagnostics, Chronic Disease Management, and Neuromodulation Therapies?

Cardiac autonomic control is increasingly central to advanced cardiovascular care as clinicians seek to better understand and manage the interplay between the autonomic nervous system (ANS) and cardiac function. This physiological domain involves the sympathetic and parasympathetic regulation of heart rate, rhythm, and vascular tone-crucial for detecting autonomic dysfunctions that contribute to conditions such as heart failure, arrhythmias, hypertension, postural tachycardia syndrome (POTS), and sudden cardiac death.

With the rise of chronic lifestyle diseases and stress-related disorders, there is growing demand for diagnostic tools and therapeutic interventions that assess and modulate cardiac autonomic activity. Cardiac autonomic biomarkers-such as heart rate variability (HRV), baroreflex sensitivity, and autonomic tone-are being leveraged for early risk stratification, therapy optimization, and prognosis in patients with cardiovascular, metabolic, and neurodegenerative disorders. This shift is embedding cardiac autonomic control into broader strategies for preventive, personalized, and neurocardiology-integrated care.

How Are Monitoring Technologies, AI Analytics, and Neuromodulation Solutions Advancing Cardiac Autonomic Control Applications?

Technology is reshaping how cardiac autonomic control is measured and managed. Wearable ECG monitors, continuous HRV tracking systems, implantable loop recorders, and smart patches are enabling non-invasive, real-time monitoring of autonomic markers in ambulatory settings. These devices support long-term rhythm tracking, stress response analysis, and autonomic function assessment without the need for complex hospital-based testing.

AI and machine learning algorithms are enhancing autonomic data interpretation, enabling personalized baselines, anomaly detection, and predictive analytics for cardiac events. This is particularly valuable in remote monitoring of high-risk cardiac patients, athletes, and individuals with autonomic disorders. On the therapeutic front, vagus nerve stimulation (VNS), spinal cord stimulation, and bioelectronic modulation are being explored to restore autonomic balance in heart failure, atrial fibrillation, and resistant hypertension.

Pharmacological research is also focusing on agents that influence autonomic tone, while integrated digital platforms are combining HRV analysis with behavioral interventions for stress and cardiac rehab programs. These innovations are making cardiac autonomic control actionable and scalable across clinical and wellness settings.

Which Clinical Applications, Regional Markets, and Research Collaborations Are Driving Growth in the Cardiac Autonomic Control Market?

Cardiac autonomic control is applied in clinical cardiology, sports medicine, sleep medicine, endocrinology, and neurology. Heart failure management, arrhythmia diagnostics, diabetic autonomic neuropathy screening, and post-MI risk stratification are among the key use cases. In sports science, HRV monitoring is used to optimize training loads and prevent overtraining. Behavioral health and biofeedback applications are also leveraging autonomic insights to support anxiety, PTSD, and burnout interventions.

North America and Europe lead in research, clinical adoption, and regulatory approvals for both diagnostic and neuromodulation technologies. Asia-Pacific is showing rapid growth through mobile health integration and wearable tech adoption, particularly in Japan, South Korea, and China. Collaborative R&D between academic institutions, medtech firms, and cardiology centers is accelerating product development and validation of autonomic markers as clinical endpoints.

Digital health startups, wellness device manufacturers, and cardiac monitoring solution providers are converging around HRV-based platforms that deliver continuous insights into autonomic function. Payers and health systems are beginning to recognize the value of autonomic data in chronic disease management and readmission reduction, further catalyzing integration into mainstream care models.

What Are the Factors Driving Growth in the Cardiac Autonomic Control Market?

The cardiac autonomic control market is expanding as the role of autonomic dysfunction becomes more deeply linked with cardiovascular outcomes, chronic disease burden, and behavioral health. As monitoring and neuromodulation technologies become more accessible, their integration into clinical decision-making and self-care models is accelerating.

Key growth drivers include increasing cardiovascular disease prevalence, demand for early diagnostic markers, rise in wearable health technologies, development of non-invasive monitoring solutions, and the therapeutic potential of autonomic modulation. Cross-disciplinary research and digital innovation are unlocking new avenues for personalized autonomic profiling.

As healthcare systems shift toward precision medicine and real-time physiological insights, could cardiac autonomic control emerge as a foundational biomarker framework for predicting, preventing, and personalizing cardiovascular and neurobehavioral health interventions?

SCOPE OF STUDY:

The report analyzes the Cardiac Autonomic Control market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Heart Rate Variability Monitors, Blood Pressure Monitors, ECG Monitors, Other Product Types); Application (Diagnostics, Therapeutics, Research); End-Use (Hospitals & Clinics, Home Uses, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â